The relationship of glycosylation and isoelectric point with tumor accumulation of avidin.

UNLABELLED Radiolabeled avidin markedly accumulated in intraperitoneal tumors and was cleared rapidly from circulation when given intraperitoneally. This study investigated the mechanisms of the tumor localization of avidin. METHODS Avidin was deglycosylated through endoglycosydase-H digestion and/or neutralized by acetylation of its lysine amino acids with acetic acid N-hydroxysuccinimide ester. Avidin and modified avidins were analyzed using sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS/PAGE) and isoelectric focusing. A tumor model was established by intraperitoneal injection of human colon cancer cells, LS180, in nude mice. Avidin and modified avidins were labeled with 111In using diethyleneamine pentaacetic acid-biotin and were administered intraperitoneally into the tumor-bearing mice. The biodistribution of radioactivity was examined 2 and 24 h postinjection. RESULTS Deglycosylated avidins revealed a major band of smaller molecules on SDS/PAGE. The isoelectric point of neutralized avidins was reduced to less than 5, whereas that of unneutralized avidins was more than 9.5. Biodistribution study demonstrated that liver uptake was decreased by deglycosylation and kidney accumulation was decreased by neutralization, respectively. The blood clearance was remarkably slowed by combined modification of deglycosylation and neutralization. The tumor uptake of radioactivity was reduced by either deglycosylation or neutralization and was further decreased with combined modification. CONCLUSION Both high glycosylation and positive charge of avidin contributed to its accumulation in tumor. This study may facilitate development of a new vehicle for the delivery of therapeutic agents to intraperitoneal tumors.

[1]  H. Sakahara,et al.  Imaging of intraperitoneal tumors with technetium-99m GSA , 1998, Annals of nuclear medicine.

[2]  H. Sakahara,et al.  Effect of administration route and dose of streptavidin or biotin on the tumor uptake of radioactivity in intraperitoneal tumor with multistep targeting. , 1998, Nuclear medicine and biology.

[3]  H. Sakahara,et al.  Avidin targeting of intraperitoneal tumor xenografts. , 1998, Journal of the National Cancer Institute.

[4]  H. Sakahara,et al.  Improved intratumoral penetration of radiolabeled streptavidin in intraperitoneal tumors pretargeted with biotinylated antibody. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  J. Geraghty,et al.  Pretargeting strategies for radio-immunoguided tumour localisation and therapy. , 1997, European journal of cancer.

[6]  H. Sakahara,et al.  Intravenous avidin chase improved localization of radiolabeled streptavidin in intraperitoneal xenograft pretargeted with biotinylated antibody. , 1997, Nuclear medicine and biology.

[7]  S. Rosebrough,et al.  Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  F. Fazio,et al.  Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  M. Wilchek,et al.  Sodium dodecyl sulfate‐polyacrylamide gel electrophoretic method for assessing the quaternary state and comparative thermostability of avidin and streptavidin , 1996, Electrophoresis.

[10]  W. Pardridge,et al.  Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization. , 1995, Journal of pharmaceutical sciences.

[11]  R. Lotan,et al.  Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. , 1995, Cancer research.

[12]  H. Sakahara,et al.  Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  K. Rice,et al.  Receptor mediated glycotargeting. , 1995, Journal of drug targeting.

[14]  F. Mangili,et al.  Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  Hisataka Kobayashi,et al.  Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a {open_quotes}chase{close_quotes} without decreased accumulation in the target tumor , 1994 .

[16]  H. Sakahara,et al.  Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  U. Bickel,et al.  Cationization of a monoclonal antibody to the human immunodeficiency virus REV protein enhances cellular uptake but does not impair antigen binding of the antibody. , 1994, Immunology letters.

[18]  T. Saga,et al.  Application of high affinity binding concept to radiolabel avidin with Tc-99m labeled biotin and the effect of pI on biodistribution. , 1994, Nuclear medicine and biology.

[19]  A. Maraveyas,et al.  Asbestos fibers in the colonic wall. , 1974, British Journal of Cancer.

[20]  S. Rosebrough Pharmacokinetics and biodistribution of radiolabeled avidin, streptavidin and biotin. , 1993, Nuclear medicine and biology.

[21]  V. Zurawski,et al.  Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. , 1992, Gynecologic oncology.

[22]  W. Pardridge,et al.  Cationization of immunoglobulin G results in enhanced organ uptake of the protein after intravenous administration in rats and primate. , 1991, The Journal of pharmacology and experimental therapeutics.

[23]  D. Snook,et al.  Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Wilchek,et al.  Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. , 1990, European journal of biochemistry.

[25]  J. Beatty,et al.  Radioimmunotherapy of human colon carcinomatosis xenograft with 90Y-ZCE025 monoclonal antibody: toxicity and tumor phenotype studies. , 1990, Cancer research.

[26]  W. Pardridge,et al.  Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M Monsigny,et al.  Endogenous Lectins and Drug Targeting , 1988, Annals of the New York Academy of Sciences.

[28]  R. Lotan,et al.  Lectins in Cancer Cells , 1988, Annals of the New York Academy of Sciences.

[29]  J. Gershoni,et al.  Biotin binding to avidin. Oligosaccharide side chain not required for ligand association. , 1987, The Biochemical journal.

[30]  W. Pardridge,et al.  Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. , 1987, The Journal of biological chemistry.

[31]  M. J. Mattes Biodistribution of antibodies after intraperitoneal or intravenous injection and effect of carbohydrate modifications. , 1987, Journal of the National Cancer Institute.

[32]  H. Gabius,et al.  Endogenous tumor lectins: overview and perspectives. , 1986, Anticancer research.

[33]  Wieman Tj,et al.  Management of malignant ascites. , 1984 .

[34]  T. Wieman,et al.  Management of malignant ascites. , 1984, Surgery, gynecology & obstetrics.

[35]  P. Stahl,et al.  Isolation and characterization of a mannose/N-acetylglucosamine/fucose-binding protein from rat liver. , 1981, The Biochemical journal.